CY1118866T1 - Αδενοϊοι της υπο-οικογενειας β των πιθηκων sadv-28,27,-29,-32,-33, και -35 και χρησεις αυτων - Google Patents
Αδενοϊοι της υπο-οικογενειας β των πιθηκων sadv-28,27,-29,-32,-33, και -35 και χρησεις αυτωνInfo
- Publication number
- CY1118866T1 CY1118866T1 CY20171100382T CY171100382T CY1118866T1 CY 1118866 T1 CY1118866 T1 CY 1118866T1 CY 20171100382 T CY20171100382 T CY 20171100382T CY 171100382 T CY171100382 T CY 171100382T CY 1118866 T1 CY1118866 T1 CY 1118866T1
- Authority
- CY
- Cyprus
- Prior art keywords
- adenovirus
- monkey adenovirus
- sadv
- monuments
- subscriptions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
- C12N2810/6018—Adenoviridae
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Παρουσιάζεται ένας ανασυνδυαστικός φορέας που περιέχει αλληλουχίες με τον αδενοϊό του πιθήκου 28, τον αδενοϊό του πιθήκου 27, τον αδενοϊό του πιθήκου 32, τον αδενοϊό του πιθήκου 33, ή/και τον αδενοϊό του πιθήκου 35 και ένα ετερόλογο γονίδιο υπό τον έλεγχο των ρυθμιστικών αλληλουχιών. Μια κυτταρική γραμμή που εκφράζει ένα ή περισσότερα γονίδια αδενοϊών -28, -27, -32, -33, ή -35 επίσης περιλαμβάνονται. Παρέχονται μέθοδοι χρήσης των φορέων και των κυτταρικών γραμμών.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US456707P | 2007-11-28 | 2007-11-28 | |
US454207P | 2007-11-28 | 2007-11-28 | |
US453307P | 2007-11-28 | 2007-11-28 | |
US453407P | 2007-11-28 | 2007-11-28 | |
US446607P | 2007-11-28 | 2007-11-28 | |
US453107P | 2007-11-28 | 2007-11-28 | |
PCT/US2008/013065 WO2009073103A2 (en) | 2007-11-28 | 2008-11-24 | Simian subfamily b adenoviruses sadv-28,27,-29,-32,-33, and -35 and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1118866T1 true CY1118866T1 (el) | 2018-01-10 |
Family
ID=40718407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171100382T CY1118866T1 (el) | 2007-11-28 | 2017-03-28 | Αδενοϊοι της υπο-οικογενειας β των πιθηκων sadv-28,27,-29,-32,-33, και -35 και χρησεις αυτων |
Country Status (20)
Country | Link |
---|---|
US (3) | US8524219B2 (el) |
EP (1) | EP2220242B1 (el) |
JP (3) | JP5740157B2 (el) |
KR (3) | KR101761683B1 (el) |
CN (1) | CN101883857B (el) |
AU (2) | AU2008331905B2 (el) |
BR (1) | BRPI0822651A2 (el) |
CA (1) | CA2706257C (el) |
CY (1) | CY1118866T1 (el) |
DK (1) | DK2220242T3 (el) |
ES (1) | ES2621165T3 (el) |
HR (1) | HRP20170395T1 (el) |
HU (1) | HUE031636T2 (el) |
LT (1) | LT2220242T (el) |
MX (2) | MX2010005859A (el) |
PL (1) | PL2220242T3 (el) |
PT (1) | PT2220242T (el) |
SG (2) | SG186022A1 (el) |
SI (1) | SI2220242T1 (el) |
WO (1) | WO2009073103A2 (el) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101883858B (zh) * | 2007-11-28 | 2015-07-22 | 宾夕法尼亚大学托管会 | 猿猴亚家族E腺病毒SAdV-39、-25.2、-26、-30、-37和-38及其应用 |
JP5661476B2 (ja) * | 2008-03-04 | 2015-01-28 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | サルアデノウイルスSAdV−36、−42.1、−42.2および−44ならびにそれらの用途 |
WO2010051367A1 (en) | 2008-10-31 | 2010-05-06 | The Trustees Of The University Of Pennsylvania | Simian adenoviruses sadv-43, -45,-48,-49, and -50 and uses thereof |
CA2762203A1 (en) | 2009-05-29 | 2010-12-02 | Soumitra Roy | Simian adenovirus 41 and uses thereof |
EP2643465B1 (en) | 2010-11-23 | 2016-05-11 | The Trustees Of The University Of Pennsylvania | Subfamily e simian adenovirus a1321 and uses thereof |
TWI623618B (zh) | 2011-07-12 | 2018-05-11 | 傳斯堅公司 | Hbv聚合酶突變體 |
WO2013045658A1 (en) | 2011-09-29 | 2013-04-04 | Transgene Sa | Immunotherapy composition and regimen for treating hepatitis c virus infection |
TW201321016A (zh) | 2011-09-29 | 2013-06-01 | Transgene Sa | 免疫療法組成物及用於治療c型肝炎病毒感染之療程(二) |
SG10201609511XA (en) | 2012-05-18 | 2016-12-29 | Univ Pennsylvania | Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof |
EP2971008B1 (en) | 2013-03-14 | 2018-07-25 | Salk Institute for Biological Studies | Oncolytic adenovirus compositions |
WO2015191508A1 (en) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
BR112017009497A2 (pt) | 2014-11-05 | 2018-02-06 | Voyager Therapeutics, Inc. | polinucleotídeos de aadc para o tratamento da doença de parkinson |
KR20230145206A (ko) | 2014-11-14 | 2023-10-17 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
BR112017010087A2 (pt) | 2014-11-14 | 2018-06-05 | Voyager Therapeutics, Inc. | composições e métodos para tratar esclerose lateral amiotrófica (ela) |
EP3230441A4 (en) | 2014-12-12 | 2018-10-03 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
EA038402B9 (ru) * | 2015-06-12 | 2021-09-22 | Глаксосмитклайн Байолоджикалс Са | Аденовирусные полинуклеотиды и полипептиды |
AU2016362477A1 (en) | 2015-12-02 | 2018-06-14 | Voyager Therapeutics, Inc. | Assays for the detection of AAV neutralizing antibodies |
JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR THE TREATMENT OF DISEASES |
WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
CA3023022A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
RU2764587C2 (ru) | 2016-05-18 | 2022-01-18 | Вояджер Терапьютикс, Инк. | Способы и композиции для лечения хореи гентингтона |
MX2018014154A (es) | 2016-05-18 | 2019-05-06 | Voyager Therapeutics Inc | Polinucleotidos moduladores. |
EP3831281A1 (en) | 2016-08-30 | 2021-06-09 | The Regents of The University of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
US20190328869A1 (en) | 2016-10-10 | 2019-10-31 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
CA3045892A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
AU2018261790A1 (en) | 2017-05-05 | 2019-11-28 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
EP3619308A4 (en) | 2017-05-05 | 2021-01-27 | Voyager Therapeutics, Inc. | COMPOSITIONS AND METHODS OF TREATMENT FOR HUNTINGTON'S MORBUS |
JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
WO2019018342A1 (en) | 2017-07-17 | 2019-01-24 | Voyager Therapeutics, Inc. | NETWORK EQUIPMENT TRACK GUIDE SYSTEM |
WO2019028306A2 (en) | 2017-08-03 | 2019-02-07 | Voyager Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR ADMINISTRATION OF ADENO-ASSOCIATED VIRUSES |
WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
EP4124658A3 (en) | 2017-10-16 | 2023-04-19 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
EP3807404A1 (en) | 2018-06-13 | 2021-04-21 | Voyager Therapeutics, Inc. | Engineered 5' untranslated regions (5' utr) for aav production |
JP2021530548A (ja) | 2018-07-24 | 2021-11-11 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics, Inc. | 遺伝子治療製剤を生産するための系および方法 |
TW202035689A (zh) | 2018-10-04 | 2020-10-01 | 美商航海家醫療公司 | 測量病毒載體粒子的效價及強度之方法 |
US20210348194A1 (en) | 2018-10-05 | 2021-11-11 | Voyager Therapeutics, Inc. | Engineered nucleic acid constructs encoding aav production proteins |
US20210395777A1 (en) | 2018-10-15 | 2021-12-23 | Voyager Therapeutics, Inc. | EXPRESSION VECTORS FOR LARGE-SCALE PRODUCTION OF rAAV IN THE BACULOVIRUS/Sf9 SYSTEM |
US20230193315A1 (en) | 2019-01-31 | 2023-06-22 | Oregon Health & Science University | Methods for using transcription-dependent directed evolution of aav capsids |
NL2023464B1 (en) * | 2019-07-09 | 2021-02-02 | Academisch Ziekenhuis Leiden | Oncolytic Non-human adenoviruses and uses thereof |
EP4178605A1 (en) | 2020-07-13 | 2023-05-17 | Transgene | Treatment of immune depression |
CA3209779A1 (en) | 2021-02-01 | 2022-08-04 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
WO2022218997A1 (en) | 2021-04-12 | 2022-10-20 | Centre National De La Recherche Scientifique (Cnrs) | Novel universal vaccine presenting system |
WO2023173114A2 (en) * | 2022-03-10 | 2023-09-14 | Technovax, Inc. | Recombinant virus-like particle capsid vaccines against adenoviruses and compositions, methods, and use thereof |
WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
CN117089577B (zh) * | 2023-08-21 | 2024-06-25 | 暨南大学 | 重组的猴腺病毒、病毒载体及构建方法 |
CN117143833B (zh) * | 2023-08-21 | 2024-06-04 | 暨南大学 | 一种猴腺病毒毒株及其应用 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2009A (en) * | 1841-03-18 | Improvement in machines for boring war-rockets | ||
US2008A (en) * | 1841-03-18 | Gas-lamp eok conducting gas pkom ah elevated buhner to one below it | ||
WO1998010087A1 (en) * | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
AU1822499A (en) | 1997-12-12 | 1999-06-28 | Saint Louis University | Ctip, a novel protein that interacts with ctbp and uses therefor |
US20040136963A1 (en) | 2001-06-22 | 2004-07-15 | The Trustees Of The University Of Pennsylvania | Simian adenovirus vectors and methods of use |
EP1409012B1 (en) * | 2001-06-22 | 2009-02-11 | The Wistar Institute Of Anatomy And Biology | Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein |
AU2002322285A1 (en) | 2001-06-22 | 2003-01-08 | The Trustees Of The University Of Pennsylvania | Method for rapid screening of bacterial transformants and novel simian adenovirus proteins |
MXPA04004876A (es) | 2001-11-21 | 2004-07-30 | Univ Pennsylvania | Secuencias de acido nucleico y de aminoacido de adenovirus de simio, vectores que contienen los mismos y metodos de uso. |
US7291498B2 (en) * | 2003-06-20 | 2007-11-06 | The Trustees Of The University Of Pennsylvania | Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses |
ES2478625T3 (es) * | 2003-06-20 | 2014-07-22 | The Trustees Of The University Of Pennsylvania | Método de generación de adenovirus quiméricos y usos de tales adenovirus quiméricos |
ATE449105T1 (de) | 2004-01-23 | 2009-12-15 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
EP1718315A4 (en) * | 2004-02-06 | 2008-08-13 | Univ Monash | HIGH-DOSE USE AND SHORT INTERVAL OF SULFATE POLYSACCHARIDES IN THE TREATMENT OF INFECTIONS |
JP5108521B2 (ja) * | 2004-10-14 | 2012-12-26 | クルセル ホランド ベー ヴェー | マラリア初回免疫/追加免疫ワクチン |
CN103088060A (zh) * | 2005-05-12 | 2013-05-08 | 葛兰素集团有限公司 | 疫苗组合物 |
PT2012822E (pt) | 2006-04-28 | 2010-04-27 | Univ Pennsylvania | Proteínas hexon de adenovirus modificadas e suas utilizações |
CN101883858B (zh) | 2007-11-28 | 2015-07-22 | 宾夕法尼亚大学托管会 | 猿猴亚家族E腺病毒SAdV-39、-25.2、-26、-30、-37和-38及其应用 |
EP2220217A2 (en) | 2007-11-28 | 2010-08-25 | The Trustees of the University of Pennsylvania | Simian subfamily c adenoviruses sadv-40, -31, and-34 and uses thereof |
-
2008
- 2008-11-24 DK DK08857781.2T patent/DK2220242T3/en active
- 2008-11-24 WO PCT/US2008/013065 patent/WO2009073103A2/en active Application Filing
- 2008-11-24 US US12/744,375 patent/US8524219B2/en active Active
- 2008-11-24 SG SG2012085635A patent/SG186022A1/en unknown
- 2008-11-24 ES ES08857781.2T patent/ES2621165T3/es active Active
- 2008-11-24 HU HUE08857781A patent/HUE031636T2/en unknown
- 2008-11-24 MX MX2010005859A patent/MX2010005859A/es active IP Right Grant
- 2008-11-24 MX MX2013010573A patent/MX344106B/es unknown
- 2008-11-24 SI SI200831779A patent/SI2220242T1/sl unknown
- 2008-11-24 KR KR1020167026644A patent/KR101761683B1/ko active IP Right Grant
- 2008-11-24 EP EP08857781.2A patent/EP2220242B1/en not_active Not-in-force
- 2008-11-24 CN CN200880118585.XA patent/CN101883857B/zh not_active Expired - Fee Related
- 2008-11-24 PL PL08857781T patent/PL2220242T3/pl unknown
- 2008-11-24 BR BRPI0822651-2A2A patent/BRPI0822651A2/pt not_active Application Discontinuation
- 2008-11-24 KR KR1020157025052A patent/KR101662571B1/ko active IP Right Grant
- 2008-11-24 KR KR1020107014131A patent/KR101614362B1/ko not_active IP Right Cessation
- 2008-11-24 SG SG10201603993TA patent/SG10201603993TA/en unknown
- 2008-11-24 LT LTEP08857781.2T patent/LT2220242T/lt unknown
- 2008-11-24 PT PT88577812T patent/PT2220242T/pt unknown
- 2008-11-24 AU AU2008331905A patent/AU2008331905B2/en not_active Ceased
- 2008-11-24 CA CA2706257A patent/CA2706257C/en not_active Expired - Fee Related
- 2008-11-24 JP JP2010535986A patent/JP5740157B2/ja not_active Expired - Fee Related
-
2013
- 2013-08-16 US US13/968,757 patent/US9206238B2/en not_active Expired - Fee Related
-
2014
- 2014-12-05 JP JP2014246762A patent/JP2015107117A/ja active Pending
- 2014-12-16 AU AU2014277699A patent/AU2014277699B2/en not_active Ceased
-
2015
- 2015-11-03 US US14/931,286 patent/US20160051603A1/en not_active Abandoned
-
2016
- 2016-05-18 JP JP2016099658A patent/JP2016214242A/ja active Pending
-
2017
- 2017-03-10 HR HRP20170395TT patent/HRP20170395T1/hr unknown
- 2017-03-28 CY CY20171100382T patent/CY1118866T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1118866T1 (el) | Αδενοϊοι της υπο-οικογενειας β των πιθηκων sadv-28,27,-29,-32,-33, και -35 και χρησεις αυτων | |
CY1118351T1 (el) | ΑΔΕΝΟΪΟΣ ΑΠΟΤΕΛΟΥΜΕΝΟΣ ΑΠΟ ΠΡΩΤΕΪΝΗ ΕΞΩΝΙΟΥ ΚΑΨΙΔΙΟΥ SAdV-39 ΑΔΕΝΟΪΟΥ Ε ΠΙΘΗΚΟΥ ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΟΥ | |
MX2010005860A (es) | Adenovirus simianos de la subfamilia c sadv-40, sadv-31 y sadv-34 y usos de los mismos. | |
SA518400623B1 (ar) | جينات ديستروفين صغير محسنة ومجموعات إظهارها واستخدامها | |
WO2009136977A3 (en) | Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof | |
CY1124341T1 (el) | Ποντικοι me εξανθρωπισμενη καθολικη ελαφρια αλυσιδα | |
PH12020500466A1 (en) | Lipid nanoparticle formulations of non-viral, capsid-free dna vectors | |
AR102420A1 (es) | Sitios de integración en celulas cho y sus usos | |
PH12021550849A1 (en) | Compositions and methods for immunotherapy | |
UY28926A1 (es) | Adenovirus quiméricos para uso en el tratamiento del cáncer | |
MX358019B (es) | Adenovirus de simio de la subfamilia e a1302, a1320, a1331 y a1337 y sus usos. | |
WO2012071318A3 (en) | Subfamily e simian adenoviruses a1321, a1325, a1295, a1309, a1316 and a1322 and uses thereof | |
CY1113713T1 (el) | Ανοσοκατασταλτικα πολυπεπτιδια και νουκλεϊκα οξεα | |
CL2018003210A1 (es) | Selección directa de células que expresan niveles altos de proteínas heterodiméricas usando vectores de complementación intragénica de glutamina sintetasa. | |
Ge et al. | A new tubRZ operon involved in the maintenance of the Bacillus sphaericus mosquitocidal plasmid pBsph | |
WO2018144087A3 (en) | Dna plasmids for the fast generation of homologous recombination vectors for cell line development | |
ATE463577T1 (de) | Plasmide mit mobilen hybridreplikationsursprüngen | |
ATE532861T1 (de) | Expressionsvektor | |
CY1124207T1 (el) | Συνδυασμοι οι οποιοι περιλαμβανουν θετικους αλλοστερικους ρυθμιστες μεταβοτροπικου γλουταμινεργικου υποδοχεα υποτυπου 2 και οι χρησεις αυτων | |
MX2018005598A (es) | Composicion de polietileno semiconductor. | |
EP4053329A4 (en) | BASE MATERIAL FIBER AND ARTIFICIAL LEATHER | |
WO2018129486A3 (en) | Composition and methods for enhanced knock-in reporter gene expression | |
WO2019018551A3 (en) | METHODS AND COMPOSITIONS FOR GENETICALLY GENETIC HANDLING OF GENES AND CELLS | |
MX2019001142A (es) | Estabilizante para dispersiones de poliolefina en poliol polieter. | |
EA201700456A1 (ru) | Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf |